Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer

MT Newswires Live12-17

Gilead Sciences (GILD) said Tuesday that its antibody-drug conjugate Trodelvy was granted US Food and Drug Administration breakthrough therapy designation for the treatment of adults with extensive-stage small cell lung cancer whose disease has progressed on or following platinum-based chemotherapy.

The designation, which speeds up the FDA approval process, was based on results from a cohort of a phase 2 trial, which showed "encouraging" results for Trodelvy as a second-line treatment for extensive-stage small cell lung cancer, the company said.

Gilead said it plans to initiate a phase 3 clinical trial in extensive-stage small cell lung cancer patients.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment